Biocept Up 72% on Covid-19 Testing Plan
April 13 2020 - 12:20PM
Dow Jones News
By Josh Beckerman
Biocept Inc. shares rose 72% to 61 cents following the company's
announcement late Thursday that it will conduct Covid-19
testing.
Biocept, which provides liquid biopsy tests for cancer patients,
said it would begin accepting physician-ordered Covid-19 testing
requests for processing April 15.
Biocept's lab will use Thermo Fisher Scientific Inc.'s TaqPath
platform and kit.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 13, 2020 13:05 ET (17:05 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2024 to May 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From May 2023 to May 2024